This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

This study has been withdrawn prior to enrollment.
(Lack of enrollment)
Information provided by (Responsible Party):
Tarix Pharmaceuticals Identifier:
First received: March 12, 2012
Last updated: August 29, 2016
Last verified: August 2016
Engraftment failure is a major obstacle to the success of cord blood transplantation in children with malignancies and inherited metabolic disorders, despite the fact that they receive relatively high doses of nucleated cells from UCB. TXA127 is pharmaceutically formulated Angiotensin 1-7 [A(1-7)], a non-hypertensive derivative of Angiotensin-II (which contains the 8th amino acid conferring receptor binding to blood pressure receptors). TXA127 has multilineage effects on hematopoietic progenitors in vitro and in vivo. Preclinical data show that TXA127 is a novel stimulator of early multilineage hematopoietic progenitors, increases engraftment of committed hematopoietic progenitors, and induces more rapid production of platelets and neutrophils in the peripheral circulation, especially in limited cell number transplants. Treatment with TXA127 following UCBT is expected to increase the numbers of hematopoietic progenitors and accelerate engraftment.

Condition Intervention Phase
Cord Blood Transplant Hematologic Malignancy Inherited Metabolic Disease Drug: TXA127 Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

Further study details as provided by Tarix Pharmaceuticals:

Primary Outcome Measures:
  • Safety of TXA127 in subjects undergoing cord blood transplantation [ Time Frame: Through Day 100 post transplant ]

Secondary Outcome Measures:
  • Effect of TXA127 on incidence, severity and duration of aGVHD [ Time Frame: Through Day 100 post transplant ]
  • Effect of TXA127 on incidence, severity and duration of mucositis [ Time Frame: Through Day 100 post transplant ]
    WHO oral toxicity score

  • Effect of TXA127 on neutrophil engraftment [ Time Frame: Through Day 100 post transplant ]
  • Effect of TXA127 on platelet recovery [ Time Frame: Through Day 100 post transplant ]
  • Effect of TXA127 on immune reconstitution [ Time Frame: Through Day 100 post transplant ]

Enrollment: 0
Study Start Date: March 2012
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 300mcg/kg/day for 28 days Drug: TXA127
300mcg/kg/day, subcutaneous injection for up to 28 days


Ages Eligible for Study:   6 Months to 20 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject, parent, or legal guardian provided written informed consent.
  • Subjects must be >6 months and <21 years of age.
  • Subjects must have one or two available 4, 5, or 6/6 antigen matching unrelated UCB unit(s) that will deliver a cell dose between 3.0-5.0 x 107cells/kg.

    • These units must be HLA-matched minimally at 4 of 6 HLA-A and B (at intermediate resolution by molecular typing) and DRB1 (at high resolution by molecular typing) loci with the subject.
    • If two CB units will be used, the units must be HLA-matched at 3 of 6 HLA- A, B, and DRB1 loci with each other (using same resolution of molecular typing as indicated above).
    • For a single unit transplant, a minimum of 3 x 107cells/kg will be required.
    • For a double unit transplant, HLA-matched units must be available such that together both units deliver a combined pre-cryopreserved nucleated cell dose of at least 4.0 x 107 cells/kg with 1 unit of at least 2.5 x 107 cells/kg and the other at least 1.5 x 107 cells/kg.
  • Subjects must have histologically confirmed diagnosis of a hematologic malignancy or a laboratory confirmed inherited metabolic disease.
  • Subjects who have had a prior autologous or allogeneic transplant are allowed to participate provided it has been >1 year since the transplant was completed.
  • Subjects must not have active CNS disease at the time of study enrollment.
  • Subjects must have a life expectancy of >4 months.
  • Female subjects capable of reproduction (defined as a subject who has started menses) must agree to the following:

    • Use of an effective oral or IM contraceptive method during the course of the study and 2 months following the last administration of study drug.
    • Female subjects capable of reproduction must have a negative pregnancy test result within 3 days prior to first study drug dose.
  • Subjects must have adequate function of other organ systems as measured by:

    • Creatinine <2.0 mg/dL and creatinine clearance >50 mL/min.
    • Hepatic transaminases (ALT/AST) <4 x ULN, bilirubin <2.0 mg/dL.
    • Adequate cardiac function by echocardiogram or MUGA scan (ejection fraction or shortening fraction >80% of normal value for age).
    • Pulmonary function tests demonstrating FVC and FEV1 of >60% of predicted. DLCO should be used for subjects >10 years old. Crying vital capacity of >60% may be substituted for subjects unable to complete PFTs.

Exclusion Criteria:

  • Subjects with an uncontrolled infection at the time of cytoreduction.
  • Subjects who are pregnant or breast feeding.
  • Subjects who are known to be seropositive for HIV or HTLV-1.
  • Subjects who have had an autologous or allogeneic transplant <1 year from the anticipated administration of the first dose of study drug.
  • Subjects who have received treatment with an investigational agent within 30 days of anticipated administration of the first dose of study drug.
  • Subjects with current alcohol use, illicit drug use or any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule.
  • Subjects must not have any co-morbid condition which, in the view of the Principal Investigators, renders the subject at too high a risk from treatment complications and regimen-related morbidity/mortality.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01554254

United States, North Carolina
Pediatric Bone and Cord Blood, Duke Univ. Med. Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
Tarix Pharmaceuticals
Principal Investigator: Kristin Page, MD Duke University
Principal Investigator: Joanne Kurtzberg, MD Duke University
  More Information

Responsible Party: Tarix Pharmaceuticals Identifier: NCT01554254     History of Changes
Other Study ID Numbers: TXA127-2010-002
Study First Received: March 12, 2012
Last Updated: August 29, 2016

Keywords provided by Tarix Pharmaceuticals:
Cord blood transplant
hematological malignancy
inherited metabolic disease
Neutrophil engraftment
Platelet recovery
Immune reconstitution

Additional relevant MeSH terms:
Metabolic Diseases
Angiotensin I (1-7)
Antihypertensive Agents
Vasodilator Agents processed this record on September 19, 2017